Price Change to Note: What Will Happen to La Jolla Pharmaceutical Company Next? The Stock Just Increased A Lot

Price Change to Note: What Will Happen to La Jolla Pharmaceutical Company Next? The Stock Just Increased A Lot

The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a huge mover today! The stock increased 4.23% or $0.77 on November 23, hitting $18.97. About 122,434 shares traded hands. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 5.01% since April 22, 2016 and is downtrending. It has underperformed by 10.42% the S&P500.
The move comes after 6 months positive chart setup for the $321.38 million company. It was reported on Nov, 24 by Barchart.com. We have $19.92 PT which if reached, will make NASDAQ:LJPC worth $16.07 million more.

Analysts await La Jolla Pharmaceutical Company (NASDAQ:LJPC) to report earnings on February, 23. They expect $-1.22 EPS, down 76.81% or $0.53 from last year’s $-0.69 per share. After $-1.23 actual EPS reported by La Jolla Pharmaceutical Company for the previous quarter, Wall Street now forecasts -0.81% EPS growth.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Out of 3 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $80.0 is the highest target while $25 is the lowest. The $52.50 average target is 176.75% above today’s ($18.97) stock price. La Jolla Pharmaceutical Company has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) earned “Buy” rating by Chardan Capital Markets on Tuesday, September 8. The firm earned “Hold” rating on Tuesday, August 11 by Zacks. The firm has “Outperform” rating by Cowen & Co given on Tuesday, February 9. The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) has “Buy” rating given on Tuesday, May 24 by Lake Street.

According to Zacks Investment Research, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.”

Insitutional Activity: The institutional sentiment decreased to 1.03 in 2016 Q2. Its down 0.87, from 1.9 in 2016Q1. The ratio turned negative, as 6 funds sold all La Jolla Pharmaceutical Company shares owned while 14 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 15.94 million shares or 0.70% less from 16.05 million shares in 2016Q1.
Gsa Cap Partners Limited Liability Partnership holds 44,900 shares or 0.04% of its portfolio. Tiaa Cref Management Ltd Com holds 43,053 shares or 0% of its portfolio. Moreover, Credit Suisse Ag has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 32,741 shares. Morgan Stanley holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 138,661 shares. Belmont Advisors Incorporated holds 0.92% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 60,000 shares. Blackrock Ltd Liability Co has invested 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Jennison Assoc Ltd Liability Com accumulated 252,437 shares or 0% of the stock. Teacher Retirement Sys Of Texas holds 2,042 shares or 0% of its portfolio. Blackrock Institutional Na holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 347,644 shares. Bank Of Mellon Corporation holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 67,369 shares. Paw accumulated 0.92% or 50,000 shares. The New Jersey-based Kcg Hldgs has invested 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Landscape Cap Mngmt Lc owns 53,254 shares or 0.11% of their US portfolio. Moreover, Franklin Res Inc has 0.01% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 965,600 shares. Moreover, Alliancebernstein Ltd Partnership has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 12,700 shares.

Insider Transactions: Since September 9, 2016, the stock had 1 buying transaction, and 0 sales for $2.76 million net activity. Shares for $2.76M were bought by TANG KEVIN C on Friday, September 9.

More notable recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Businesswire.com which released: “La Jolla Pharmaceutical Company Announces Agreement with European Medicines …” on September 07, 2016, also Businesswire.com with their article: “La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan …” published on October 24, 2016, Businesswire.com published: “La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies …” on June 06, 2016. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) were released by: Businesswire.com and their article: “La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results …” published on May 06, 2016 as well as Businesswire.com‘s news article titled: “La Jolla Pharmaceutical Company to Provide Corporate Overview at the Cowen and …” with publication date: March 03, 2016.

LJPC Company Profile

La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. The Company’s product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment